Updates on Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder - 10/08/18
Résumé |
Transcranial magnetic stimulation has emerged as a treatment option for treatment-resistant depression. While existing data largely support efficacy of transcranial magnetic stimulation for major depressive disorder, ongoing research aims to optimize treatment parameters and identify biomarkers of treatment response. In this article, the authors describe data from controlled trials and ongoing efforts to enhance transcranial magnetic stimulation outcomes for major depressive disorder. Findings from preliminary research aimed at identifying neuroimaging and neurophysiological biomarkers of transcranial magnetic stimulation effects are discussed.
Le texte complet de cet article est disponible en PDF.Keywords : Noninvasive neuromodulation, Depression, Treatment-resistant depression, Transcranial magnetic stimulation
Plan
Disclosure Statement: Dr L.L. Carpenter has received consulting income from Magstim, LTD, and Drs N.S. Philip and L.L. Carpenter have received clinical trials/research support from Neuronetics, Neosync, and Janssen. Dr N.S. Philip has been an unpaid scientific advisory board member for Neuronetics. None of the other authors has any relevant commercial or financial disclosures to report. |
|
This work was supported in part by grants from the National Institute of Mental Health (NIMH) (R25MH101076; S. Yuan & H. Wang) and the US Department of Veterans Affairs (IK2CX000724 and I01RX002450; N.S. Philip). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of NIMH or Department of Veterans Affairs. |
Vol 41 - N° 3
P. 419-431 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?